Selegiline is a selective inhibitor of brain monoamine oxidase (MAO) type B. MAO-B is involved in enzymatic degradation of the endogenous dopamine and also in Levodopa’ degradation.
- Treatment of Parkinson’s disease, or symptomatic Parkinsonism
Jamax is indicated for treatment of Parkinson’s disease, or symptomatic Parkinsonism, alone or in combination with Levodopa, with or without enzyme inhibitor. In the early stages of the Parkinson’s disease Jamax can be used to delay the administration of Levodopa (with or without decarboxylase inhibitor).
Sufficient results are obtained when administering Jamax alone in the early or mid stages of the disease.
The administration of Jamax relives but does not prevent the development of symptoms and does not improve the mobility without additional administration of Levodopa (with or without decarboxylase inhibitor).
Jamax may be applied in the late stages of the disease to increase the effectiveness of Levodopa, especially in patients who are suffering from on / off or other symptoms that may be associated with a reduction in the effectiveness of treatment.
Subject to medical prescription
Pharmaceutical form: 5 mg x 30 tablets
NHIF code: NF 367 ICD: G20